Eli Lilly Acquires Psychedelic Drug Developer AtaiBeckley for $2.8 Billion
On July 16, 2026, Eli Lilly announced its acquisition of AtaiBeckley for up to $3.8 billion ($2.8 billion upfront plus $1 billion in milestones), gaining access to late-stage psychedelic treatments for mental health, including a DMT-based nasal spray for treatment-resistant depression. The deal follows President Trump’s April executive order accelerating psychedelic therapy approvals. Shares of AtaiBeckley surged over 50% on the news, reflecting growing pharmaceutical industry interest in psychedelic-based therapies.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
Eli Lilly Acquires AtaiBeckley for $2.8 Billion; Cathie Wood Favors Compass Pathways
Eli Lilly has agreed to acquire psychedelic drug developer AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, signaling major pharma interest in psychedelic medicine. The deal follows regulatory shifts, including an FDA executive order and finalized psychedelic drug guidance. Meanwhile, Cathie Wood's Ark Genomic Revolution ETF sold 1.1 million shares of AtaiBeckley and bought nearly 400,000 shares of Compass Pathways, which is developing COMP360, a psilocybin therapy for treatment-resistant depression. Compass has completed phase 3 trials meeting primary endpoints and plans to submit a rolling NDA by Q4 2026, aiming for launch readiness by year-end 2026. Wood's move suggests she sees Compass as a better bet due to its proximity to market approval.
Eli Lilly's Acquisition of AtaiBeckley Signals Big Pharma Embrace of Psychedelic Drugs for Mental Health
Eli Lilly announced it will acquire clinical-stage psychedelic drug maker AtaiBeckley for up to $3.8 billion, marking a major endorsement of psychedelic medications for mental health treatment. The deal follows positive clinical trial results and President Trump's April executive order fast-tracking FDA reviews of such drugs. AtaiBeckley's lead asset, BPL-003, a synthetic 5-MeO-DMT nasal spray for treatment-resistant depression, has Breakthrough Therapy Designation and is in Phase 3 trials. Analysts estimate a potential $1-2 billion market opportunity if approved by early 2029. The article notes that psychedelics like psilocybin, MDMA, and LSD are being tested for depression, PTSD, anxiety, and addiction, with experts calling them a potential paradigm shift in psychiatry. J&J's ketamine-derived Spravato remains the current market leader with $2 billion in projected annual sales.
Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion in Psychedelic Drug Push
Eli Lilly announced an agreement to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, with up to $1 billion in additional payments contingent on milestones. The deal gives Lilly access to BPL-003, a psychedelic-based nasal spray shown to reduce treatment-resistant depression with a single dose. This marks Big Pharma's latest foray into psychedelics, following AbbVie's $1.2 billion deal for Gilgamesh Pharmaceuticals and J&J's growing Spravato sales. The acquisition comes after the White House ordered the FDA in April 2026 to fast-track psychedelic research and approvals. Analysts estimate the psychedelic market could generate $7 billion in annual sales by 2032. Lilly, known for its weight-loss drugs Mounjaro and Zepbound, is leveraging its financial strength to expand into neuroscience, building on its legacy with Prozac and its Alzheimer's treatment.
Show 9 older updatesHide older updates
AtaiBeckley Stock Soars on Eli Lilly Acquisition Deal
Shares of AtaiBeckley (NASDAQ: ATAI) surged on July 16, 2026, after the mental health biotech company agreed to be acquired by pharmaceutical giant Eli Lilly (NYSE: LLY). Under the deal, Lilly will pay $6.75 per share in cash upfront, equating to roughly $2.8 billion, plus up to $2.50 per share in milestone payments tied to development and regulatory goals, potentially totaling $3.8 billion. AtaiBeckley's stock closed at $5.36 the prior day. The acquisition is expected to close in the third quarter, pending shareholder and regulatory approval. AtaiBeckley focuses on novel depression treatments, including its lead drug BPL-003, a synthetic psychedelic nasal spray for treatment-resistant depression currently in Phase 3 trials after receiving FDA Breakthrough Therapy Designation. The article also includes promotional content for Motley Fool's Stock Advisor service.
AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion
On July 16, 2026, clinical-stage mental health and psychedelic drug developer AtaiBeckley (NASDAQ:ATAI) surged 33.4% to close at $7.15 after pharmaceutical giant Eli Lilly (NYSE:LLY) announced its acquisition in a deal worth up to $3.8 billion. The deal includes $6.75 in cash per share plus $2.50 in contingent value rights (CVRs) tied to milestones for two of AtaiBeckley's treatments over the next four to seven years. Trading volume reached 164.9 million shares, approximately 1,494% above its three-month average. The broader market declined, with the S&P 500 falling 0.50% to 7,535 and the Nasdaq Composite falling 1.47% to 25,882. COMPASS Pathways fell 6.61% amid mixed psychedelics sentiment. The article notes AtaiBeckley's stock has doubled over the past year, partly due to the Trump administration's positive outlook on psychedelic treatments.
Eli Lilly Acquires AtaiBeckley in $2.8 Billion Psychedelic Medicine Deal
Eli Lilly (LLY) announced a definitive agreement to acquire AtaiBeckley (ATAI) for $2.8 billion in cash, with potential additional payments of up to $1 billion through contingent value rights tied to regulatory and developmental milestones. The deal, representing a 25% premium on AtaiBeckley's previous close, marks Lilly's first major entry into psychedelic medicine. The centerpiece is BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression, which has entered pivotal late-stage clinical trials. The acquisition diversifies Lilly's pipeline beyond its blockbuster weight-loss and diabetes drugs Mounjaro and Zepbound, positioning it to compete in neuropsychiatry. BPL-003 offers rapid antidepressant effects with a two-hour clinic-friendly treatment window. Lilly shares rose 0.85% on the news, and Wall Street maintains a 'Strong Buy' consensus with a mean price target of nearly $1,290, implying about 9% upside.
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Eli Lilly announced on July 16, 2026, that it will acquire AtaiBeckley for up to $3.8 billion, including $2.8 billion upfront and up to $1 billion in milestone payments. The deal gives Lilly access to BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression. This acquisition follows a directive from U.S. President Donald Trump in April to speed up reviews of certain psychedelic treatments and increase federal research funding. The move places Lilly among major pharma companies investing in psychedelic therapies, following AbbVie's $1.2 billion deal with Gilgamesh Pharmaceuticals in 2025. The acquisition is expected to close in the third quarter of 2026 and is part of Lilly's broader strategy to diversify beyond its cardiometabolic franchise into neuroscience, immunology, and oncology.
Eli Lilly Enters Psychedelic Drug Race with Up to $3.8 Billion AtaiBeckley Acquisition
Eli Lilly announced on July 16, 2026, its acquisition of AtaiBeckley for up to $3.8 billion, including $2.8 billion upfront and up to $1 billion in milestone payments. The deal gives Lilly access to BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression. This move follows President Trump's April directive to speed up regulatory reviews and increase federal funding for psychedelic treatments. The acquisition reflects growing pharmaceutical industry interest in psychedelic therapies for mental health disorders, with AbbVie having made a similar deal in 2025. Lilly's purchase is its latest neuroscience investment, following its $7.8 billion Centessa Pharmaceuticals acquisition in June 2026. The company is leveraging cash from its obesity drug sales to expand into immunology, oncology, and neuroscience.
Eli Lilly to Acquire Psychedelic Drugmaker AtaiBeckley for $2.8 Billion
Eli Lilly has agreed to acquire AtaiBeckley, a clinical-stage biotechnology company focused on psychedelic-based mental health treatments, for $6.75 per share in cash, totaling approximately $2.8 billion. The deal includes up to an additional $1 billion in contingent payments tied to regulatory milestones. AtaiBeckley's lead drug, BPL-003, is a synthetic DMT nasal spray for treatment-resistant depression, which has shown durable symptom reduction in Phase 2b trials and received FDA Breakthrough Therapy Designation. Phase 3 results are expected in 2029. The pipeline also includes VLS-01 (DMT buccal film) and EMP-01 (MDMA compound for social anxiety). The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals. This acquisition is part of a broader expansion by Lilly beyond its core obesity and diabetes business, having already committed over $10 billion in upfront payments across eight acquisitions in 2026.
Eli Lilly to Buy Psychedelics Maker AtaiBeckley for $2.8 Billion
Eli Lilly announced the acquisition of psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, with potential additional milestone payments of up to $1 billion. The deal gives Lilly access to AtaiBeckley's lead drug BPL-003, a DMT-based nasal spray in Phase 3 trials for treatment-resistant depression, as well as an MDMA-related compound. Initial Phase 3 results are expected in 2029. The acquisition price of $6.75 per share represents a 26% premium over the previous close. This marks growing momentum for psychedelic-based mental health treatments, supported by the Trump administration's prioritization of such therapies. The deal is part of Lilly's broader spending spree, having already committed over $10 billion upfront on eight acquisitions this year as the world's most valuable healthcare company.
AtaiBeckley Surges on Report Eli Lilly in Talks to Buy Psychedelic Drug Developer
Shares of AtaiBeckley surged 50% in premarket trading on July 16, 2026, following a Bloomberg report that Eli Lilly is in advanced talks to acquire the psychedelic drug developer as soon as this week. The deal could exceed $2 billion, with BMO Capital Markets noting that ongoing talks with other pharmaceutical companies might support a higher price. The rally was also fueled by President Donald Trump's April executive order aimed at accelerating access to psychedelic-based treatments, which had already sparked an industrywide rally. AtaiBeckley focuses on psychedelic treatments for mental health, including BPL-003 for treatment-resistant depression. Other psychedelic drug developers like Compass Pathways, GH Research, Definium Therapeutics, and Enveric Biosciences also saw premarket gains. Eli Lilly shares were flat. RBC Capital Markets said the sector is poised to go mainstream. Lilly has been active in neuroscience acquisitions, including the $7.8 billion buyout of Centessa Pharmaceuticals.
AtaiBeckley shares soar on reports of potential Eli Lilly takeover talks
Shares of AtaiBeckley (ATAI) surged up to 53% in premarket trading on July 16, 2026, following reports that Eli Lilly (LLY) is in discussions to acquire the psychedelic drug developer. According to BMO Capital Markets analyst Evan David Seigerman, the acquisition would strengthen Eli Lilly's presence in psychiatry and support its strategy of diversifying beyond its core cardiometabolic business. Seigerman noted that AtaiBeckley's late-stage neuropsychiatric pipeline, including VLS-01 for treatment-resistant depression and EMP-01 for social anxiety disorder, could add strategic value to Lilly's long-term neuroscience portfolio. Neither company has publicly confirmed any agreement, and discussions remain ongoing.